产品介绍 评论(0)
宿主来源
Rat抗原名称
IL-23 (p19)分子别名
Interleukin-23 subunit alpha; IL-23 subunit alpha; IL-23-A; Interleukin-23 subunit p19 (IL-23p19); SGRF; IL23A细胞定位
SecretedAccession
Q9NPF7, P29460克隆号
S-2754抗体类型
Rat mAb抗体同种型
Rat IgG1,k反应种属 ?
Ms纯化方式
Protein G浓度
5 mg/ml纯度
>95% (Determined by SDS-PAGE)内毒素含量
<2EU/mg标记
Unconjugated性状
Liquid缓冲体系
PBS pH7.4, containing no preservative
储存条件
2 to 8 °C for 2 weeks under sterile conditions;
-20 °C for 3 months under sterile conditions;
-80 °C for 24 months under sterile conditions.
Please avoid repeated freeze-thaw cycles.应用
in vivo IL-23p19 neutralization ,in vitro IL-23p19 neutralization ,WB稀释度
应用 稀释度 推荐种属 WB 1:1000 Ms
Interleukin-23 (IL-23) is a heterodimeric cytokine composed of a p19 subunit and a p40 subunit. The p19 subunit is unique to IL-23, while the p40 subunit is shared with IL-12. IL-23 plays a crucial role in the immune system, particularly in the regulation of T cell responses. It is involved in the differentiation and maintenance of Th17 cells, a subset of T helper cells that produce pro-inflammatory cytokines such as IL-17 and IL-22. These Th17 cells are essential for host defense against extracellular pathogens but can also contribute to chronic inflammation and autoimmune diseases when dysregulated. IL-23 signaling occurs through the IL-23 receptor complex, which includes IL-23R and IL-12Rβ1 subunits, and activates downstream pathways like JAK-STAT, leading to the production of various inflammatory mediators. Due to its involvement in immune-mediated inflammatory diseases, IL-23 has become a target for therapeutic interventions, with several biologics targeting the p19 subunit or the IL-23 receptor being developed and used in the treatment of conditions such as psoriasis, Crohn’s disease, and other autoimmune disorders.
免疫印迹
WB result of Invivo anti-mouse IL-23 (p19) Recombinant mAb
Primary antibody: Invivo anti-mouse IL-23 (p19) Recombinant mAb at 1/1000 dilution
Lane 1: IL-23 Protein, Mouse 1 µg
Lane 2: IL-23 Protein, Human 1 µg
Secondary antibody: Goat Anti-Rat IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 21 kDa
Observed MW: 17 kDa

评论(0)